Synchron Raises $200 Million Series D to Advance BCI Commercialization and Next-Gen Technology
Synchron announced the successful completion of a $200 million Series D funding round to push forward the commercialization of its brain-computer interface (BCI) system. Based in New York, the company will utilize this capital to speed up bringing its Stentrode BCI to market and to further develop an advanced generation of the device.
Funding and Strategic Plans
- The latest funding round increases Synchron’s total capital raised to $345 million.
- Proceeds will accelerate pivotal clinical trials aimed at launching Stentrode.
- Expansion includes recruiting more engineers, neuroscientists, and operators to progress next-generation BCI technologies.
- A Cognitive AI division in New York will focus on training models to decode brain signals in real time.
- A new engineering hub in San Diego has been established to build advanced brain interface technologies.
Investors and Partnerships
- Double Point Ventures led the Series D round.
- Existing investors such as ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS participated.
- New investors include the Australian National Reconstruction Fund, T.Rx Capital, Qatar Investment Authority, K5 Global, Protocol Labs, and IQT.
About Stentrode BCI
"Stentrode — which is implanted through an endovascular approach — detects motor intention from blood vessels within the brain."
Synchron emphasizes that its system uniquely accesses blood vessels to capture brain signals. The implant is positioned on the motor cortex surface via the jugular vein, enabling detection of motor commands.
Author's summary
Synchron’s $200M Series D funding fuels the launch of its innovative Stentrode BCI and the development of cutting-edge brain-computer interfaces, backed by a diversified investor base and expanded R&D efforts.
more
MassDevice — 2025-11-07